Infusion of ex vivo-cultured allogeneic NK cels in acute myeloid leukemia patients not eligible for stem cell transplantation (a phase I dose escalation study)

Trial Profile

Infusion of ex vivo-cultured allogeneic NK cels in acute myeloid leukemia patients not eligible for stem cell transplantation (a phase I dose escalation study)

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs GCT NK cell therapy (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms PMLA25
  • Most Recent Events

    • 20 Jan 2016 New trial record
    • 08 Dec 2015 Results (n=12) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top